StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

Summary

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion ($2.8 billion upfront) to expand its neuroscience portfolio with the psychedelic drug candidate BPL-003. The deal is expected to close in Q3 2026.